CO6251282A2 - Oxazolidinonas sustituidas y su uso - Google Patents
Oxazolidinonas sustituidas y su usoInfo
- Publication number
- CO6251282A2 CO6251282A2 CO09144718A CO09144718A CO6251282A2 CO 6251282 A2 CO6251282 A2 CO 6251282A2 CO 09144718 A CO09144718 A CO 09144718A CO 09144718 A CO09144718 A CO 09144718A CO 6251282 A2 CO6251282 A2 CO 6251282A2
- Authority
- CO
- Colombia
- Prior art keywords
- formula
- oxazolidinones
- diseases
- replaced
- prophylaxis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención se refiere a nuevas oxazolidinonas sustituidas de fórmula (I), a procedimientos para su preparación, a su uso para el tratamiento y/o profilaxis de enfermedades así como a su uso para la preparación de medicamentos para el tratamiento y/o profilaxis de enfermedades, de forma particular de enfermedades tromboembólicas. Fórmula (I) con R' = fórmula (la), (Ib), (Ic), (Id), (le), (If), (lg), (lh) o (Ii). 1.- Compuesto de fórmula en la que R1 representa un grupo de fórmulaen donde # es el punto de unión al anillo de fenilo, R4 representa hidrógeno o alquilo C1-C3, en el que alquilo puede estar sustituido con un sustituyente, seleccionándose el sustituyente del grupo constituido por hidroxi, ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007028320A DE102007028320A1 (de) | 2007-06-20 | 2007-06-20 | Substituierte Oxazolidinone und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6251282A2 true CO6251282A2 (es) | 2011-02-21 |
Family
ID=39765012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09144718A CO6251282A2 (es) | 2007-06-20 | 2009-12-17 | Oxazolidinonas sustituidas y su uso |
Country Status (26)
Country | Link |
---|---|
US (1) | US20100184767A1 (es) |
EP (1) | EP2167495A1 (es) |
JP (1) | JP2010530385A (es) |
KR (1) | KR20100029213A (es) |
CN (1) | CN101772496A (es) |
AR (1) | AR067058A1 (es) |
AU (1) | AU2008266527A1 (es) |
BR (1) | BRPI0813263A2 (es) |
CA (1) | CA2692172A1 (es) |
CL (1) | CL2008001703A1 (es) |
CO (1) | CO6251282A2 (es) |
CR (1) | CR11169A (es) |
DE (1) | DE102007028320A1 (es) |
DO (1) | DOP2009000287A (es) |
EC (1) | ECSP099806A (es) |
GT (1) | GT200900318A (es) |
IL (1) | IL202073A0 (es) |
MA (1) | MA31570B1 (es) |
MX (1) | MX2009013710A (es) |
PA (1) | PA8784101A1 (es) |
PE (1) | PE20090333A1 (es) |
RU (1) | RU2010101302A (es) |
TN (1) | TN2009000484A1 (es) |
TW (1) | TW200914447A (es) |
UY (1) | UY31136A1 (es) |
WO (1) | WO2008155034A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102464658B (zh) * | 2010-11-03 | 2014-04-16 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
CA2824885A1 (en) | 2011-01-19 | 2012-07-26 | Bayer Intellectual Property Gmbh | Binding proteins to inhibitors of coagulation factors |
CZ2012114A3 (cs) * | 2012-02-17 | 2013-02-20 | Zentiva, K.S. | Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu |
US20150299160A1 (en) * | 2012-04-16 | 2015-10-22 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban and intermediates thereof |
WO2014012360A1 (en) * | 2012-07-18 | 2014-01-23 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous heterocyclic derivatives and their application in drugs |
CN102746250B (zh) * | 2012-07-24 | 2016-03-02 | 瑞阳制药有限公司 | N-[[3-(3-氟-4-吗啉基-4-基-苯基)-2-恶唑酮基-5-基]甲基]-2-甲氨基-苯甲酰胺的制备方法 |
CN103833724A (zh) * | 2012-11-20 | 2014-06-04 | 上海医药工业研究院 | 一种5-氯噻吩-2-甲酰氯的制备方法 |
CN104163819A (zh) * | 2013-05-17 | 2014-11-26 | 天津药物研究院 | 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途 |
CN103242307B (zh) * | 2013-05-17 | 2015-08-12 | 天津药物研究院有限公司 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
BR112015031291A2 (pt) | 2013-06-20 | 2017-07-25 | Bayer Cropscience Ag | derivados de sulfureto de arila e derivados de arilalquil sulfóxido como acaricidas e inseticidas |
US9981928B2 (en) | 2013-06-20 | 2018-05-29 | Bayer Cropscience Aktiengesellschaft | Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides |
US9783509B2 (en) | 2013-07-08 | 2017-10-10 | Bayer Cropscience Aktiengesellschaft | Six-membered C-N-linked aryl sulfide derivatives and aryl sulfoxide derivatives as pest conrol agents |
CN104016975B (zh) * | 2014-06-27 | 2017-01-11 | 深圳翰宇药业股份有限公司 | 利伐沙班的制备方法 |
CN104447729A (zh) * | 2014-12-05 | 2015-03-25 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
JP7205529B2 (ja) * | 2018-02-26 | 2023-01-17 | 住友化学株式会社 | オキサゾリジノン化合物の製造方法 |
KR102422628B1 (ko) | 2020-03-20 | 2022-07-18 | 마인도어 사회적협동조합 | 보드 게임 도구 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
DE4319041A1 (de) | 1992-10-23 | 1994-04-28 | Bayer Ag | Trisubstituierte Biphenyle |
HUP0001115A3 (en) | 1996-10-14 | 2001-06-28 | Bayer Ag | Heterocyclylmethyl-substituted pyrazol derivatives, process for their preparation and pharmaceuticals containing the same |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
DE19920352A1 (de) | 1999-05-04 | 2000-11-09 | Bayer Ag | Substituiertes Pyrazolderivat |
DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19962924A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
GB0405272D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
DE102007028406A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007032347A1 (de) * | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
DE102007032345A1 (de) * | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
-
2007
- 2007-06-20 DE DE102007028320A patent/DE102007028320A1/de not_active Withdrawn
-
2008
- 2008-06-07 AU AU2008266527A patent/AU2008266527A1/en not_active Abandoned
- 2008-06-07 KR KR1020097026531A patent/KR20100029213A/ko not_active Application Discontinuation
- 2008-06-07 MX MX2009013710A patent/MX2009013710A/es not_active Application Discontinuation
- 2008-06-07 WO PCT/EP2008/004564 patent/WO2008155034A1/de active Application Filing
- 2008-06-07 CN CN200880020715A patent/CN101772496A/zh active Pending
- 2008-06-07 RU RU2010101302/04A patent/RU2010101302A/ru not_active Application Discontinuation
- 2008-06-07 JP JP2010512561A patent/JP2010530385A/ja active Pending
- 2008-06-07 EP EP08759100A patent/EP2167495A1/de not_active Withdrawn
- 2008-06-07 US US12/665,727 patent/US20100184767A1/en not_active Abandoned
- 2008-06-07 CA CA002692172A patent/CA2692172A1/en not_active Abandoned
- 2008-06-07 BR BRPI0813263-1A2A patent/BRPI0813263A2/pt not_active Application Discontinuation
- 2008-06-10 PA PA20088784101A patent/PA8784101A1/es unknown
- 2008-06-10 UY UY31136A patent/UY31136A1/es not_active Application Discontinuation
- 2008-06-10 CL CL2008001703A patent/CL2008001703A1/es unknown
- 2008-06-11 PE PE2008000991A patent/PE20090333A1/es not_active Application Discontinuation
- 2008-06-19 AR ARP080102608A patent/AR067058A1/es unknown
- 2008-06-19 TW TW097122782A patent/TW200914447A/zh unknown
-
2009
- 2009-11-12 IL IL202073A patent/IL202073A0/en unknown
- 2009-11-18 TN TNP2009000484A patent/TN2009000484A1/fr unknown
- 2009-12-15 GT GT200900318A patent/GT200900318A/es unknown
- 2009-12-15 EC EC2009009806A patent/ECSP099806A/es unknown
- 2009-12-15 CR CR11169A patent/CR11169A/es not_active Application Discontinuation
- 2009-12-16 DO DO2009000287A patent/DOP2009000287A/es unknown
- 2009-12-17 CO CO09144718A patent/CO6251282A2/es not_active Application Discontinuation
-
2010
- 2010-01-19 MA MA32537A patent/MA31570B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
PE20090333A1 (es) | 2009-04-15 |
DE102007028320A1 (de) | 2008-12-24 |
BRPI0813263A2 (pt) | 2014-12-30 |
TW200914447A (en) | 2009-04-01 |
UY31136A1 (es) | 2009-01-30 |
AU2008266527A1 (en) | 2008-12-24 |
IL202073A0 (en) | 2010-06-16 |
CR11169A (es) | 2010-07-01 |
PA8784101A1 (es) | 2009-02-09 |
WO2008155034A1 (de) | 2008-12-24 |
MX2009013710A (es) | 2010-02-01 |
ECSP099806A (es) | 2010-01-29 |
EP2167495A1 (de) | 2010-03-31 |
JP2010530385A (ja) | 2010-09-09 |
DOP2009000287A (es) | 2010-01-31 |
AR067058A1 (es) | 2009-09-30 |
KR20100029213A (ko) | 2010-03-16 |
MA31570B1 (fr) | 2010-08-02 |
CA2692172A1 (en) | 2008-12-24 |
TN2009000484A1 (en) | 2011-03-31 |
RU2010101302A (ru) | 2011-07-27 |
US20100184767A1 (en) | 2010-07-22 |
CN101772496A (zh) | 2010-07-07 |
CL2008001703A1 (es) | 2008-12-26 |
GT200900318A (es) | 2010-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6251282A2 (es) | Oxazolidinonas sustituidas y su uso | |
CO6351738A2 (es) | Compuestos organicos | |
CR20120264A (es) | Compuestos | |
SV2008003045A (es) | Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes | |
PA8809001A1 (es) | Compuestos organicos | |
MA33768B1 (fr) | Triazolopyridines | |
PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
ECSP14004812A (es) | Triazolopiridinas sustituidas | |
SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
BR112014014909A2 (pt) | agonistas de tgr5 não sistêmicos | |
PE20151892A1 (es) | Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas | |
PA8772701A1 (es) | "COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO)-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA" | |
NI201500134A (es) | Derivados de 2-((4-amino-3-(3-flúor-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il) metil)-3-(2-(trifluorometil)bencil)quinazolina-4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasas | |
AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
AR066981A1 (es) | Oxazolidinonas sustituidas y su uso | |
UY32131A (es) | Compuestos de anillo fusionado y uso de los mismos | |
NI201100117A (es) | Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2. | |
UY31781A (es) | Derivados de iminopiridina y su uso | |
UY32748A (es) | 2-carboxamida-cicloamino-ureas | |
UY32747A (es) | 2-carboxamida-cicloamino-ureas sustituidas | |
UY32408A (es) | Macrolido anti-inflamatorio | |
ECSP10010642A (es) | Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes | |
UY31161A1 (es) | Usos de derivados de cinolina en el tratamiento de la esquizofrenia | |
AR095353A1 (es) | Compuesto | |
UY32191A (es) | Derivados de iminopiridina y uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |